Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1997 Dec;6(5-6):303–309. doi: 10.1080/09629359791424

Somatostatin in inflammatory bowel disease

J D Van Bergeijk 1,✉, J H P Wilson 1
PMCID: PMC2365882  PMID: 18472863

Abstract

Intestinal inflammation is controlled by various immunomodulating cells, interacting by molecular mediators. Neuropeptides, released by enteric nerve cells and neuroendocrine mucosa cells, are able to affect several aspects of the general and intestinal immune system, with both pro- as well as anti-inflammatory activities. In inflammatory bowel disease (IBD) there is both morphological as well as experimental evidence for involvement of neuropeptides in the pathogenesis. Somatostatin is the main inhibitory peptide in inflammatory processes, and its possible role in IBD is discussed.

Full Text

The Full Text of this article is available as a PDF (175.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Accili E. A., Dhatt N., Buchan A. M. Neural somatostatin, vasoactive intestinal polypeptide and substance P in canine and human jejunum. Neurosci Lett. 1995 Feb 6;185(1):37–40. doi: 10.1016/0304-3940(94)11219-9. [DOI] [PubMed] [Google Scholar]
  2. Agro A., Padol I., Stanisz A. M. Immunomodulatory activities of the somatostatin analogue BIM 23014c: effects on murine lymphocyte proliferation and natural killer activity. Regul Pept. 1991 Feb 1;32(2):129–139. doi: 10.1016/0167-0115(91)90041-e. [DOI] [PubMed] [Google Scholar]
  3. Battershill P. E., Clissold S. P. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs. 1989 Nov;38(5):658–702. doi: 10.2165/00003495-198938050-00002. [DOI] [PubMed] [Google Scholar]
  4. Bauer W., Briner U., Doepfner W., Haller R., Huguenin R., Marbach P., Petcher T. J., Pless SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982 Sep 13;31(11):1133–1140. doi: 10.1016/0024-3205(82)90087-x. [DOI] [PubMed] [Google Scholar]
  5. Bell G. I., Yasuda K., Kong H., Law S. F., Raynor K., Reisine T. Molecular biology of somatostatin receptors. Ciba Found Symp. 1995;190:65–88. doi: 10.1002/9780470514733.ch5. [DOI] [PubMed] [Google Scholar]
  6. Bhathena S. J., Louie J., Schechter G. P., Redman R. S., Wahl L., Recant L. Identification of human mononuclear leukocytes bearing receptors for somatostatin and glucagon. Diabetes. 1981 Feb;30(2):127–131. doi: 10.2337/diab.30.2.127. [DOI] [PubMed] [Google Scholar]
  7. Binimelis J., Webb S. M., Monés J., Serrano J., Casamitjana R., Elena M., Peinado M. A., Vilardell F., De Leiva A. Circulating immunoreactive somatostatin in gastrointestinal diseases. Decrease after vagotomy and enhancement in active ulcerative colitis, irritable bowel syndrome, and duodenal ulcer. Scand J Gastroenterol. 1987 Oct;22(8):931–937. doi: 10.3109/00365528708991938. [DOI] [PubMed] [Google Scholar]
  8. Bishop A. E., Polak J. M., Bryant M. G., Bloom S. R., Hamilton S. Abnormalities of vasoactive intestinal polypeptide-containing nerves in Crohn's disease. Gastroenterology. 1980 Nov;79(5 Pt 1):853–860. [PubMed] [Google Scholar]
  9. Blum A. M., Metwali A., Cook G., Mathew R. C., Elliott D., Weinstock J. V. Substance P modulates antigen-induced, IFN-gamma production in murine Schistosomiasis mansoni. J Immunol. 1993 Jul 1;151(1):225–233. [PubMed] [Google Scholar]
  10. Blum A. M., Metwali A., Mathew R. C., Cook G., Elliott D., Weinstock J. V. Granuloma T lymphocytes in murine schistosomiasis mansoni have somatostatin receptors and respond to somatostatin with decreased IFN-gamma secretion. J Immunol. 1992 Dec 1;149(11):3621–3626. [PubMed] [Google Scholar]
  11. Bruns C., Raulf F., Hoyer D., Schloos J., Lübbert H., Weckbecker G. Binding properties of somatostatin receptor subtypes. Metabolism. 1996 Aug;45(8 Suppl 1):17–20. doi: 10.1016/s0026-0495(96)90072-4. [DOI] [PubMed] [Google Scholar]
  12. Burroughs A. K. Octreotide in variceal bleeding. Gut. 1994;35(3 Suppl):S23–S27. doi: 10.1136/gut.35.3_suppl.s23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Calam J., Ghatei M. A., Domin J., Adrian T. E., Myszor M., Gupta S., Tait C., Bloom S. R. Regional differences in concentrations of regulatory peptides in human colon mucosal biopsy. Dig Dis Sci. 1989 Aug;34(8):1193–1198. doi: 10.1007/BF01537267. [DOI] [PubMed] [Google Scholar]
  14. Church M. K., Benyon R. C., Lowman M. A., Hutson P. A., Holgate S. T. Allergy or inflammation? From neuropeptide stimulation of human skin mast cells to studies on the mechanism of the late asthmatic response. Agents Actions. 1989 Jan;26(1-2):22–30. doi: 10.1007/BF02126554. [DOI] [PubMed] [Google Scholar]
  15. Coy D. H., Taylor J. E. Receptor-specific somatostatin analogs: correlations with biological activity. Metabolism. 1996 Aug;45(8 Suppl 1):21–23. doi: 10.1016/s0026-0495(96)90073-6. [DOI] [PubMed] [Google Scholar]
  16. Crowe R., Kamm M. A., Burnstock G., Lennard-Jones J. E. Peptide-containing neurons in different regions of the submucous plexus of human sigmoid colon. Gastroenterology. 1992 Feb;102(2):461–467. doi: 10.1016/0016-5085(92)90091-c. [DOI] [PubMed] [Google Scholar]
  17. Dawson J., Bryant M. G., Bloom S. R., Peters T. J. Gastrointestinal regulatory peptide storage granule abnormalities in jejunal mucosal diseases. Gut. 1984 Jun;25(6):636–643. doi: 10.1136/gut.25.6.636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Dorta G., Schnegg J. F., Saraga E., Schmied P. A. Treatment of gold-induced enteritis with octreotide. Lancet. 1993 Jul 17;342(8864):179–179. doi: 10.1016/0140-6736(93)91386-z. [DOI] [PubMed] [Google Scholar]
  19. Duffy L. C., Zielezny M. A., Riepenhoff-Talty M., Byers T. E., Marshall J., Weiser M. M., Graham S., Ogra P. L. Vasoactive intestinal peptide as a laboratory supplement to clinical activity index in inflammatory bowel disease. Dig Dis Sci. 1989 Oct;34(10):1528–1535. doi: 10.1007/BF01537105. [DOI] [PubMed] [Google Scholar]
  20. Eglezos A., Andrews P. V., Helme R. D. In vivo inhibition of the rat primary antibody response to antigenic stimulation by somatostatin. Immunol Cell Biol. 1993 Apr;71(Pt 2):125–129. doi: 10.1038/icb.1993.13. [DOI] [PubMed] [Google Scholar]
  21. Eliakim R., Karmeli F., Okon E., Rachmilewitz D. Octreotide effectively decreases mucosal damage in experimental colitis. Gut. 1993 Feb;34(2):264–269. doi: 10.1136/gut.34.2.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Eliakim R., Rachmilewitz D. Inflammatory mediators and the pathogenesis of inflammatory bowel disease. Ital J Gastroenterol. 1992 Jul-Aug;24(6):361–368. [PubMed] [Google Scholar]
  23. Elitsur Y., Luk G. D. Gastrointestinal neuropeptides suppress human colonic lamina propria lymphocyte DNA synthesis. Peptides. 1990 Sep-Oct;11(5):879–894. doi: 10.1016/0196-9781(90)90002-m. [DOI] [PubMed] [Google Scholar]
  24. Elliott D. E., Metwali A., Blum A. M., Sandor M., Lynch R., Weinstock J. V. T lymphocytes isolated from the hepatic granulomas of schistosome-infected mice express somatostatin receptor subtype II (SSTR2) messenger RNA. J Immunol. 1994 Aug 1;153(3):1180–1186. [PubMed] [Google Scholar]
  25. Elliott D. E., Weinstock J. V. Granulomas in murine schistosomiasis mansoni have a somatostatin immunoregulatory circuit. Metabolism. 1996 Aug;45(8 Suppl 1):88–90. doi: 10.1016/s0026-0495(96)90093-1. [DOI] [PubMed] [Google Scholar]
  26. Fais S., Annibale B., Boirivant M., Santoro A., Pallone F., Delle Fave G. Effects of somatostatin on human intestinal lamina propria lymphocytes. Modulation of lymphocyte activation. J Neuroimmunol. 1991 Mar;31(3):211–219. doi: 10.1016/0165-5728(91)90042-6. [DOI] [PubMed] [Google Scholar]
  27. Fehér E., Fodor M., Burnstock G. Distribution of somatostatin-immunoreactive nerve fibres in Peyer's patches. Gut. 1992 Sep;33(9):1195–1198. doi: 10.1136/gut.33.9.1195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ferri G. L., Adrian T. E., Allen J. M., Soimero L., Cancellieri A., Yeats J. C., Blank M., Polak J. M., Bloom S. R. Intramural distribution of regulatory peptides in the sigmoid-recto-anal region of the human gut. Gut. 1988 Jun;29(6):762–768. doi: 10.1136/gut.29.6.762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Fóris G., Gyimesi E., Komáromi I. The mechanism of antibody-dependent cellular cytotoxicity stimulation by somatostatin in rat peritoneal macrophages. Cell Immunol. 1985 Jan;90(1):217–225. doi: 10.1016/0008-8749(85)90183-2. [DOI] [PubMed] [Google Scholar]
  30. Goetzl E. J., Payan D. G. Inhibition by somatostatin of the release of mediators from human basophils and rat leukemic basophils. J Immunol. 1984 Dec;133(6):3255–3259. [PubMed] [Google Scholar]
  31. Goldin E., Karmeli F., Selinger Z., Rachmilewitz D. Colonic substance P levels are increased in ulcerative colitis and decreased in chronic severe constipation. Dig Dis Sci. 1989 May;34(5):754–757. doi: 10.1007/BF01540348. [DOI] [PubMed] [Google Scholar]
  32. Hörsch D., Fink T., Göke B., Arnold R., Büchler M., Weihe E. Distribution and chemical phenotypes of neuroendocrine cells in the human anal canal. Regul Pept. 1994 Dec 15;54(2-3):527–542. doi: 10.1016/0167-0115(94)90550-9. [DOI] [PubMed] [Google Scholar]
  33. Johansson O., Sandberg G. Effect of the neuropeptides beta-MSH, neurotensin, NPY, PHI, somatostatin and substance P on proliferation of lymphocytes in vitro. Acta Physiol Scand. 1989 Sep;137(1):107–111. doi: 10.1111/j.1748-1716.1989.tb08726.x. [DOI] [PubMed] [Google Scholar]
  34. Karalis K., Mastorakos G., Chrousos G. P., Tolis G. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest. 1994 May;93(5):2000–2006. doi: 10.1172/JCI117193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Kataeva G., Agro A., Stanisz A. M. Substance-P-mediated intestinal inflammation: inhibitory effects of CP 96,345 and SMS 201-995. Neuroimmunomodulation. 1994 Nov-Dec;1(6):350–356. doi: 10.1159/000097187. [DOI] [PubMed] [Google Scholar]
  36. Keränen U., Järvinen H., Kiviluoto T., Kivilaakso E., Soinila S. Substance P- and vasoactive intestinal polypeptide-immunoreactive innervation in normal and inflamed pouches after restorative proctocolectomy for ulcerative colitis. Dig Dis Sci. 1996 Aug;41(8):1658–1664. doi: 10.1007/BF02087921. [DOI] [PubMed] [Google Scholar]
  37. Keränen U., Kiviluoto T., Järvinen H., Bäck N., Kivilaakso E., Soinila S. Changes in substance P-immunoreactive innervation of human colon associated with ulcerative colitis. Dig Dis Sci. 1995 Oct;40(10):2250–2258. doi: 10.1007/BF02209015. [DOI] [PubMed] [Google Scholar]
  38. Kimura M., Masuda T., Hiwatashi N., Toyota T., Nagura H. Changes in neuropeptide-containing nerves in human colonic mucosa with inflammatory bowel disease. Pathol Int. 1994 Aug;44(8):624–634. doi: 10.1111/j.1440-1827.1994.tb01723.x. [DOI] [PubMed] [Google Scholar]
  39. Koch T. R., Carney J. A., Go V. L. Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel diseases. Dig Dis Sci. 1987 Apr;32(4):369–376. doi: 10.1007/BF01296290. [DOI] [PubMed] [Google Scholar]
  40. Koch T. R., Carney J. A., Morris V. A., Go V. L. Somatostatin in the idiopathic inflammatory bowel diseases. Dis Colon Rectum. 1988 Mar;31(3):198–203. doi: 10.1007/BF02552546. [DOI] [PubMed] [Google Scholar]
  41. Kolasinski S. L., Haines K. A., Siegel E. L., Cronstein B. N., Abramson S. B. Neuropeptides and inflammation. A somatostatin analog as a selective antagonist of neutrophil activation by substance P. Arthritis Rheum. 1992 Apr;35(4):369–375. doi: 10.1002/art.1780350402. [DOI] [PubMed] [Google Scholar]
  42. Krenning E. P., Kooij P. P., Pauwels S., Breeman W. A., Postema P. T., De Herder W. W., Valkema R., Kwekkeboom D. J. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion. 1996;57 (Suppl 1):57–61. doi: 10.1159/000201398. [DOI] [PubMed] [Google Scholar]
  43. Kyösola K., Penttilä O., Salaspuro M. Rectal mucosal adrenergic innervation and enterochromaffin cells in ulcerative colitis and irritable colon. Scand J Gastroenterol. 1977;12(3):363–367. doi: 10.3109/00365527709180942. [DOI] [PubMed] [Google Scholar]
  44. Lamberts S. W., Krenning E. P., Reubi J. C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 1991 Nov;12(4):450–482. doi: 10.1210/edrv-12-4-450. [DOI] [PubMed] [Google Scholar]
  45. Lamberts S. W., van der Lely A. J., de Herder W. W., Hofland L. J. Octreotide. N Engl J Med. 1996 Jan 25;334(4):246–254. doi: 10.1056/NEJM199601253340408. [DOI] [PubMed] [Google Scholar]
  46. Lotz M., Vaughan J. H., Carson D. A. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science. 1988 Sep 2;241(4870):1218–1221. doi: 10.1126/science.2457950. [DOI] [PubMed] [Google Scholar]
  47. MacDermott R. P. Alterations in the mucosal immune system in ulcerative colitis and Crohn's disease. Med Clin North Am. 1994 Nov;78(6):1207–1231. doi: 10.1016/s0025-7125(16)30096-7. [DOI] [PubMed] [Google Scholar]
  48. Mantyh C. R., Vigna S. R., Bollinger R. R., Mantyh P. W., Maggio J. E., Pappas T. N. Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis. Gastroenterology. 1995 Sep;109(3):850–860. doi: 10.1016/0016-5085(95)90394-1. [DOI] [PubMed] [Google Scholar]
  49. Mantyh P. W., Catton M., Maggio J. E., Vigna S. R. Alterations in receptors for sensory neuropeptides in human inflammatory bowel disease. Adv Exp Med Biol. 1991;298:253–283. doi: 10.1007/978-1-4899-0744-8_24. [DOI] [PubMed] [Google Scholar]
  50. Mathew R. C., Cook G. A., Blum A. M., Metwali A., Felman R., Weinstock J. V. Vasoactive intestinal peptide stimulates T lymphocytes to release IL-5 in murine schistosomiasis mansoni infection. J Immunol. 1992 Jun 1;148(11):3572–3577. [PubMed] [Google Scholar]
  51. Matucci-Cerinic M., Borrelli F., Generini S., Cantelmo A., Marcucci I., Martelli F., Romagnoli P., Bacci S., Conz A., Marinelli P. Somatostatin-induced modulation of inflammation in experimental arthritis. Arthritis Rheum. 1995 Nov;38(11):1687–1693. doi: 10.1002/art.1780381122. [DOI] [PubMed] [Google Scholar]
  52. Mayer L., Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest. 1990 Oct;86(4):1255–1260. doi: 10.1172/JCI114832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Metwali A., Blum A., Mathew R., Sandor M., Lynch R. G., Weinstock J. V. Modulation of T lymphocyte proliferation in mice infected with Schistosoma mansoni: VIP suppresses mitogen- and antigen-induced T cell proliferation possibly by inhibiting IL-2 production. Cell Immunol. 1993 Jun;149(1):11–23. doi: 10.1006/cimm.1993.1132. [DOI] [PubMed] [Google Scholar]
  54. Miller G. V., Preston S. R., Woodhouse L. F., Farmery S. M., Primrose J. N. Somatostatin binding in human gastrointestinal tissues: effect of cations and somatostatin analogues. Gut. 1993 Oct;34(10):1351–1356. doi: 10.1136/gut.34.10.1351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Mulvihill S. J., Pappas T. N., Fonkalsrud E. W., Debas H. T. The effect of somatostatin on experimental intestinal obstruction. Ann Surg. 1988 Feb;207(2):169–173. doi: 10.1097/00000658-198802000-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Neil G. A., Blum A., Weinstock J. V. Substance P but not vasoactive intestinal peptide modulates immunoglobulin secretion in murine schistosomiasis. Cell Immunol. 1991 Jul;135(2):394–401. doi: 10.1016/0008-8749(91)90284-i. [DOI] [PubMed] [Google Scholar]
  57. Niessner M., Volk B. A. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol. 1995 Sep;101(3):428–435. doi: 10.1111/j.1365-2249.1995.tb03130.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Nio D. A., Moylan R. N., Roche J. K. Modulation of T lymphocyte function by neuropeptides. Evidence for their role as local immunoregulatory elements. J Immunol. 1993 Jun 15;150(12):5281–5288. [PubMed] [Google Scholar]
  59. Nordlind K., Mutt V. Influence of beta-endorphin, somatostatin, substance P and vasoactive intestinal peptide on the proliferative response of human peripheral blood T lymphocytes to mercuric chloride. Int Arch Allergy Appl Immunol. 1986;80(3):326–328. doi: 10.1159/000234073. [DOI] [PubMed] [Google Scholar]
  60. Pascual D. W., Bost K. L. Substance P production by P388D1 macrophages: a possible autocrine function for this neuropeptide. Immunology. 1990 Sep;71(1):52–56. [PMC free article] [PubMed] [Google Scholar]
  61. Pataky D. M., Curtis S. B., Buchan A. M. The co-localization of neuropeptides in the submucosa of the small intestine of normal Wistar and non-diabetic BB rats. Neuroscience. 1990;36(1):247–254. doi: 10.1016/0306-4522(90)90366-c. [DOI] [PubMed] [Google Scholar]
  62. Patel Y. C., Wheatley T., Ning C. Multiple forms of immunoreactive somatostatin: comparison of distribution in neural and nonneural tissues and portal plasma of the rat. Endocrinology. 1981 Dec;109(6):1943–1949. doi: 10.1210/endo-109-6-1943. [DOI] [PubMed] [Google Scholar]
  63. Pawlikowski M., Stepien H., Kunert-Radek J., Schally A. V. Effect of somatostatin on the proliferation of mouse spleen lymphocytes in vitro. Biochem Biophys Res Commun. 1985 May 31;129(1):52–55. doi: 10.1016/0006-291x(85)91401-9. [DOI] [PubMed] [Google Scholar]
  64. Pawlikowski M., Stepień H., Kunert-Radek J., Zelazowski P., Schally A. V. Immunomodulatory action of somatostatin. Ann N Y Acad Sci. 1987;496:233–239. doi: 10.1111/j.1749-6632.1987.tb35771.x. [DOI] [PubMed] [Google Scholar]
  65. Payan D. G., Hess C. A., Goetzl E. J. Inhibition by somatostatin of the proliferation of T-lymphocytes and Molt-4 lymphoblasts. Cell Immunol. 1984 Apr 1;84(2):433–438. doi: 10.1016/0008-8749(84)90117-5. [DOI] [PubMed] [Google Scholar]
  66. Payer J., Huorka M., Duris I., Mikulecky M., Kratochvílová H., Ondrejka P., Lukác L. Plasma somatostatin levels in ulcerative colitis. Hepatogastroenterology. 1994 Dec;41(6):552–553. [PubMed] [Google Scholar]
  67. Payer J., Huorka M., Duris I., Mikulecký M., Kratochvíl'ová H., Ondrejka P. Circadian rhythmicity and cross correlation of plasma gastrin, cortisol and somatostatin levels in ulcerative colitis patients and healthy subjects. Hepatogastroenterology. 1993 Jun;40(3):272–275. [PubMed] [Google Scholar]
  68. Peck R. Neuropeptides modulating macrophage function. Ann N Y Acad Sci. 1987;496:264–270. doi: 10.1111/j.1749-6632.1987.tb35774.x. [DOI] [PubMed] [Google Scholar]
  69. Penman E., Wass J. A., Butler M. G., Penny E. S., Price J., Wu P., Rees L. H. Distribution and characterisation of immunoreactive somatostatin in human gastrointestinal tract. Regul Pept. 1983 Sep;7(1):53–65. doi: 10.1016/0167-0115(83)90281-1. [DOI] [PubMed] [Google Scholar]
  70. Probert L., De Mey J., Polak J. M. Ultrastructural localization of four different neuropeptides within separate populations of p-type nerves in the guinea pig colon. Gastroenterology. 1983 Nov;85(5):1094–1104. [PubMed] [Google Scholar]
  71. Rabbani S. N., Patel Y. C. Peptides derived by processing of rat prosomatostatin near the amino-terminus: characterization, tissue distribution, and release. Endocrinology. 1990 Apr;126(4):2054–2061. doi: 10.1210/endo-126-4-2054. [DOI] [PubMed] [Google Scholar]
  72. Reichlin S. Neuroendocrine-immune interactions. N Engl J Med. 1993 Oct 21;329(17):1246–1253. doi: 10.1056/NEJM199310213291708. [DOI] [PubMed] [Google Scholar]
  73. Reubi J. C., Horisberger U., Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction? Int J Cancer. 1994 Mar 1;56(5):681–688. doi: 10.1002/ijc.2910560513. [DOI] [PubMed] [Google Scholar]
  74. Reubi J. C., Horisberger U., Waser B., Gebbers J. O., Laissue J. Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology. 1992 Oct;103(4):1207–1214. doi: 10.1016/0016-5085(92)91505-x. [DOI] [PubMed] [Google Scholar]
  75. Reubi J. C., Laissue J., Waser B., Horisberger U., Schaer J. C. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci. 1994 Sep 15;733:122–137. doi: 10.1111/j.1749-6632.1994.tb17262.x. [DOI] [PubMed] [Google Scholar]
  76. Reubi J. C., Mazzucchelli L., Laissue J. A. Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease. Gastroenterology. 1994 Apr;106(4):951–959. doi: 10.1016/0016-5085(94)90754-4. [DOI] [PubMed] [Google Scholar]
  77. Reubi J. C. Somatostatin receptors in the gastrointestinal tract in health and disease. Yale J Biol Med. 1992 Sep-Oct;65(5):493–536. [PMC free article] [PubMed] [Google Scholar]
  78. Roberts A. I., Taunk J., Ebert E. C. Human lymphocytes lack substance P receptors. Cell Immunol. 1992 May;141(2):457–465. doi: 10.1016/0008-8749(92)90163-j. [DOI] [PubMed] [Google Scholar]
  79. Scicchitano R., Dazin P., Bienenstock J., Payan D. G., Stanisz A. M. The murine IgA-secreting plasmacytoma MOPC-315 expresses somatostatin receptors. J Immunol. 1988 Aug 1;141(3):937–941. [PubMed] [Google Scholar]
  80. Segura J. J., Guerrero J. M., López-Gonzalez M. A., Calvo J. R. Vasoactive intestinal peptide (VIP) inhibits substrate adherence capacity of rat peritoneal macrophages by a mechanism that involves cAMP. Cell Adhes Commun. 1993 Dec;1(3):213–221. doi: 10.3109/15419069309097255. [DOI] [PubMed] [Google Scholar]
  81. Shulkes A. Somatostatin: physiology and clinical applications. Baillieres Clin Endocrinol Metab. 1994 Jan;8(1):215–236. doi: 10.1016/s0950-351x(05)80232-0. [DOI] [PubMed] [Google Scholar]
  82. Sreedharan S. P., Kodama K. T., Peterson K. E., Goetzl E. J. Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem. 1989 Jan 15;264(2):949–952. [PubMed] [Google Scholar]
  83. Stanisz A. M., Befus D., Bienenstock J. Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from Peyer's patches, mesenteric lymph nodes, and spleen. J Immunol. 1986 Jan;136(1):152–156. [PubMed] [Google Scholar]
  84. Tang S. C., Braunsteiner H., Wiedermann C. J. Regulation of human T lymphoblast growth by sensory neuropeptides: augmentation of cholecystokinin-induced inhibition of Molt-4 proliferation by somatostatin and vasoactive intestinal peptide in vitro. Immunol Lett. 1992 Dec;34(3):237–242. doi: 10.1016/0165-2478(92)90219-e. [DOI] [PubMed] [Google Scholar]
  85. Teitelbaum D. H., Del Valle J., Reyas B., Post L., Gupta A., Mosely R. L., Merion R. Intestinal intraepithelial lymphocytes influence the production of somatostatin. Surgery. 1996 Aug;120(2):227–233. doi: 10.1016/s0039-6060(96)80292-3. [DOI] [PubMed] [Google Scholar]
  86. Uribe A., Alam M., Johansson O., Midtvedt T., Theodorsson E. Microflora modulates endocrine cells in the gastrointestinal mucosa of the rat. Gastroenterology. 1994 Nov;107(5):1259–1269. doi: 10.1016/0016-5085(94)90526-6. [DOI] [PubMed] [Google Scholar]
  87. Vanhagen P. M., Krenning E. P., Reubi J. C., Kwekkeboom D. J., Bakker W. H., Mulder A. H., Laissue I., Hoogstede H. C., Lamberts S. W. Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med. 1994 Jun;21(6):497–502. doi: 10.1007/BF00173035. [DOI] [PubMed] [Google Scholar]
  88. Watanabe T., Kubota Y., Sawada T., Muto T. Distribution and quantification of somatostatin in inflammatory disease. Dis Colon Rectum. 1992 May;35(5):488–494. doi: 10.1007/BF02049408. [DOI] [PubMed] [Google Scholar]
  89. Weinstock J. V., Blum A. M., Khetarpal S. Granulomas in murine schistosomiasis mansoni contain vasoactive intestinal peptide-responsive lymphocytes. Cell Immunol. 1991 May;134(2):458–472. doi: 10.1016/0008-8749(91)90317-5. [DOI] [PubMed] [Google Scholar]
  90. Weinstock J. V., Blum A. M., Malloy T. Macrophages within the granulomas of murine Schistosoma mansoni are a source of a somatostatin 1-14-like molecule. Cell Immunol. 1990 Dec;131(2):381–390. doi: 10.1016/0008-8749(90)90262-p. [DOI] [PubMed] [Google Scholar]
  91. Weinstock J. V., Blum A. M. Release of substance P by granuloma eosinophils in response to secretagogues in murine schistosomiasis mansoni. Cell Immunol. 1990 Feb;125(2):380–385. doi: 10.1016/0008-8749(90)90092-6. [DOI] [PubMed] [Google Scholar]
  92. Yamamoto H., Morise K., Kusugami K., Furusawa A., Konagaya T., Nishio Y., Kaneko H., Uchida K., Nagai H., Mitsuma T. Abnormal neuropeptide concentration in rectal mucosa of patients with inflammatory bowel disease. J Gastroenterol. 1996 Aug;31(4):525–532. doi: 10.1007/BF02355052. [DOI] [PubMed] [Google Scholar]
  93. van Hagen P. M., Krenning E. P., Kwekkeboom D. J., Reubi J. C., Anker-Lugtenburg P. J., Löwenberg B., Lamberts S. W. Somatostatin and the immune and haematopoetic system; a review. Eur J Clin Invest. 1994 Feb;24(2):91–99. doi: 10.1111/j.1365-2362.1994.tb00972.x. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES